Cat. No. 1370
Chemical Name: (E)-D-erythro-2-amino-1-(dihydrogenphosphate)-4-octadecene-1,3-diol
Biological ActivityEndogenous second messenger involved in the control of cell proliferation and motility, and Ca2+ mobilization. Acts as an agonist at sphingosine-1-phosphate receptors (S1P1-5) and as an activator of GPR3, GPR6 and GPR12. Effectors regulated include p38 MAP kinase, PLC, adenylyl cyclase, myosin light chain phosphatase and focal adhesion kinase.
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Certificate of Analysis / Safety Data Sheet
van Koppen et al (1996) Activation of a high affinity Gi protein-coupled plasma membrane receptor by sphingosine-1-phosphate. J.Biol.Chem. 271 2082. PMID: 8567663.
Pyne and Pyne (2000) Sphingosine 1-phosphate signalling via the endothelial differentiation gene family of G-protein-coupled receptors. Pharmacol.Ther. 88 115. PMID: 11150592.
Essler et al (2002) Sphingosine 1-phosphate dynamically regulates myosin light chain phosphatase activity in human endothelial cells. Cell.Signal. 14 607. PMID: 11955953.
Uhlenbrock et al (2002) Sphingosine 1-phosphate is a ligand of the human gpr3, gpr6 and gpr12 family of constitutively active G protein-coupled receptors. Cell.Signal. 14 941. PMID: 12220620.
If you know of a relevant citation for this product please let us know.
View Related Products by Target
Keywords: Sphingosine-1-phosphate, supplier, Endogenous, agonists, S1P1, S1P2, S1P3, S1P4, S1P5, Receptors, EDG, Sphingosine-1-Phosphate, GPR3, GPR6, GPR12
Find multiple products by catalog number
New Products in this Area
LPA1 and LPA3 receptor antagonistCYM 50358 hydrochloride
Potent and selective S1P4 antagonist(±)-AMG 487
CXCR3 antagonist; inhibits cell migration and metastasisGW 627368
Selective EP4 receptor competitive antagonistLUF 6283
HCA2 (GPR109A) partial agonistNS 304
Selective prostacyclin IP1 receptor agonistCYM 5541
Selective S1P3 receptor allosteric agonistTC LPA5 4
LPA5 receptor antagonistGSA 10
Smo receptor agonist
Potent, selective LRRK2 inhibitor
Tocris is the first to launch GSK2578215A, licensed from GlaxoSmithKline, for the study of Parkinson's Disease.